AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10828666 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy with Gleason score 2-4
Number of subjects: 134
Study 10828666 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy with Gleason score 5-7
Number of subjects: 134
Study 10828666 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy with Gleason score 8-10
Number of subjects: 134
Study 10828666 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy with Gleason score <7
Number of subjects: 134
Study 10828666 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy with Gleason score <7 and prostatectomy specimen with Gleason score 7
Number of subjects: 134
Study 8844506 — intervention group
Group type: EXPERIMENTAL
Intervention: EPD (enzyme‐potentiated desensitization)
Number of subjects: 20
Study 8844506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8421415 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 225
Study 8421415 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin sodium/sulbactam sodium
Number of subjects: 225
Study 8421415 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin/sulbactam
Number of subjects: 225
Study 3766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.5 mg)
Number of subjects: 6
Study 3766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg)
Number of subjects: 6
Study 3766497 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (20 mg)
Number of subjects: 6
Study 3766497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29346579 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management program
Number of subjects: 110
Study 29346579 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 110
Study 26813451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACET) 500 mg for two consecutive days
Number of subjects: 11
Study 26813451 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched control group)
Number of subjects: 11
Study 26813451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACET)
Number of subjects: 11
Study 24716739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg per day for two days)
Number of subjects: 48
Study 24716739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24716739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate and Placebo (both groups receive paracetamol)
Number of subjects: 48
Study 23025844 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes (as a risk factor)
Number of subjects: 823
Study 19674927 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Education Program Parkinson (PEPP)
Number of subjects: 110
Study 19674927 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 19256179 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT curriculum delivered by high school (HS) students over 12 weeks
Number of subjects: 75
Study 19256179 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 75
Study 19256179 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT curriculum
Number of subjects: 75
Study 15981758 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTF
Number of subjects: 93
Study 15981758 — intervention group
Group type: COMPARATOR
Intervention: RUTF supplement
Number of subjects: 93
Study 15981758 — intervention group
Group type: COMPARATOR
Intervention: Blended maize/soy flour
Number of subjects: 93
Study 12892329 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical impedance measurement over BCC lesions (19 lesions)
Number of subjects: 24
Study 12892329 — intervention group
Group type: COMPARATOR
Intervention: Electrical impedance measurement over benign lesions (11 lesions)
Number of subjects: 24
Study 12892329 — intervention group
Group type: COMPARATOR
Intervention: Electrical impedance measurement over normal skin (24 patients)
Number of subjects: 24
Study 10368993 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-receptor antagonist (H2-RA)
Number of subjects: 0
Study 10368993 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 0
Study 8813472 — intervention group
Group type: EXPERIMENTAL
Intervention: [111In‐DTPA-D-Phe1]octreotide (OCT)
Number of subjects: 350
Study 8813472 — intervention group
Group type: COMPARATOR
Intervention: Conventional imaging techniques (CON)
Number of subjects: 350
Study 8813472 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT radionuclide therapy
Number of subjects: 350
Study 8813472 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 350
Study 2002132 — intervention group
Group type: EXPERIMENTAL
Intervention: Together group (patients attended the program with their spouses)
Number of subjects: 49
Study 2002132 — intervention group
Group type: COMPARATOR
Intervention: Alone group (patients participated by themselves)
Number of subjects: 49
Study 2002132 — intervention group
Group type: EXPERIMENTAL
Intervention: Together group (women)
Number of subjects: 49
Study 2002132 — intervention group
Group type: COMPARATOR
Intervention: Alone group (men)
Number of subjects: 49
Study 6397178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for one month
Number of subjects: 18
Study 6397178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100-400 mg/day for six months
Number of subjects: 18
Study 6397178 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 18
Study 31108379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) combined with medication (n = 92)
Number of subjects: 167
Study 31108379 — intervention group
Group type: COMPARATOR
Intervention: Medication alone (n = 75)
Number of subjects: 167
Study 30202186 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Engagement and Planning (CEP)
Number of subjects: 394
Study 30202186 — intervention group
Group type: COMPARATOR
Intervention: Resources for Services (RS)
Number of subjects: 394
Study 27510285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser (10,600 nm, power 25 W) - 3 sessions
Number of subjects: 17
Study 27510285 — intervention group
Group type: COMPARATOR
Intervention: Low-dose UVA-1 phototherapy (30 J/cm2, 340-400 nm) - 30 sessions
Number of subjects: 17
Study 25415157 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 200
Study 25415157 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping
Number of subjects: 200
Study 22309796 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-appropriate family-based interventions developed through community collaboration; specific dosage and duration not mentioned.
Number of subjects: 0
Study 22309796 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement strategies for participants to enhance motivation for behavior changes after brief programs; specific details not mentioned.
Number of subjects: 0
Study 22309796 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of behavior changes; specific methods not mentioned.
Number of subjects: 0
Study 20932272 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 101
Study 20932272 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 101
Study 17659972 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment (continue steroids once daily for 12 months)
Number of subjects: 406
Study 17659972 — intervention group
Group type: COMPARATOR
Intervention: Short-term treatment (stop topical steroid treatment)
Number of subjects: 406
Study 15915612 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component health assessment
Number of subjects: 620
Study 11902625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearfully attached individuals
Number of subjects: 0
Study 11902625 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoccupied and dismissive individuals
Number of subjects: 0
Study 11902625 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecurely attached individuals
Number of subjects: 0
Study 10102462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet alone (3.6 g omega3 fatty acids/day)
Number of subjects: 55
Study 10102462 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise alone (55‐65% VO2max)
Number of subjects: 55
Study 10102462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fish diet and moderate exercise
Number of subjects: 55
Study 10102462 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet alone
Number of subjects: 55
Study 10102462 — intervention group
Group type: COMPARATOR
Intervention: Control group (low‐fat diet without fish and exercise)
Number of subjects: 55
Study 7597630 — intervention group
Group type: EXPERIMENTAL
Intervention: Titaniumtetrafluoride solution
Number of subjects: 30
Study 7597630 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 30
Study 2185664 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein refeeding (80 g protein)
Number of subjects: 10
Study 2185664 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate refeeding (80 g carbohydrate)
Number of subjects: 10
Study 2185664 — intervention group
Group type: COMPARATOR
Intervention: Prolonged fasting
Number of subjects: 10
Study 696985 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta2-sympathomimetic (ritodrine)
Number of subjects: 0
Study 696985 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30925861 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple mediator analysis for trans-eQTLs
Number of subjects: 0
Study 30925861 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mediation effect (TME) test
Number of subjects: 0
Study 30925861 — intervention group
Group type: EXPERIMENTAL
Intervention: Component-wise mediation effects (CME) test
Number of subjects: 0
Study 30925861 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis with multiple mediators
Number of subjects: 0
Study 28434157 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 1007
Study 28434157 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aspirin
Number of subjects: 1007
Study 28434157 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg aspirin
Number of subjects: 1007
Study 26175097 — intervention group
Group type: EXPERIMENTAL
Intervention: NZBC extract (300 mg day(‐1) CurraNZ™ containing 105 mg anthocyanin)
Number of subjects: 14
Study 26175097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, 300 mg microcrystalline cellulose M102)
Number of subjects: 14
Study 24749261 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged femoral nerve blockade
Number of subjects: 17
Study 24749261 — intervention group
Group type: COMPARATOR
Intervention: Epidural infusion of naropine
Number of subjects: 17
Study 20532965 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of another person's win in a gamble (first experiment)
Number of subjects: 60
Study 20532965 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of another person's win acknowledged as fortuitous (second experiment)
Number of subjects: 60
Study 19726588 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain intake (highest quartile)
Number of subjects: 434
Study 19726588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fiber intake (highest quartile)
Number of subjects: 434
Study 19726588 — intervention group
Group type: COMPARATOR
Intervention: Refined grain intake
Number of subjects: 434
Study 19726588 — intervention group
Group type: COMPARATOR
Intervention: Total fiber, vegetable or fruit fiber intake
Number of subjects: 434
Study 17023088 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscous fiber-containing nutrition bars (VF)
Number of subjects: 99
Study 17023088 — intervention group
Group type: COMPARATOR
Intervention: Commercial nutrition control bars (CH)
Number of subjects: 99
Study 15482401 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine + Artesunate (AQ + AS)
Number of subjects: 308
Study 15482401 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine (AQ)
Number of subjects: 308
Study 11572027 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch (pouch group)
Number of subjects: 42
Study 11572027 — intervention group
Group type: COMPARATOR
Intervention: Straight coloanal anastomosis (straight group)
Number of subjects: 42
Study 11572027 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 9757987 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (25 microg/kg)
Number of subjects: 26
Study 9757987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7521832 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency treatment of seizures and aggressive treatment of fever
Number of subjects: 0
Study 7521832 — intervention group
Group type: EXPERIMENTAL
Intervention: Further evaluation including neuroimaging, electroencephalogram, and developmental assessment
Number of subjects: 0
Study 7521832 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with an antiepileptic drug
Number of subjects: 0
Study 2844494 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 7
Study 2844494 — intervention group
Group type: COMPARATOR
Intervention: Conversion enzyme inhibitor
Number of subjects: 7
Study 29462158 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day DHA (from algal oil) for 16 weeks
Number of subjects: 376
Study 29462158 — intervention group
Group type: COMPARATOR
Intervention: Placebo: taste/color matched corn/soybean oil for 16 weeks
Number of subjects: 376
Study 28267152 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 60
Study 28267152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26448371 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure irrigation (>20 psi)
Number of subjects: 2447
Study 26448371 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure irrigation (5 to 10 psi)
Number of subjects: 2447
Study 26448371 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low pressure irrigation (1 to 2 psi)
Number of subjects: 2447
Study 26448371 — intervention group
Group type: EXPERIMENTAL
Intervention: Castile soap irrigation
Number of subjects: 2447
Study 26448371 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 2447
Study 24245738 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PCAD
Number of subjects: 57
Study 24245738 — intervention group
Group type: COMPARATOR
Intervention: Controls without CAD
Number of subjects: 57
Study 21145198 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV Symptom Management Self-Efficacy for Women Scale (HSM-SEWS)
Number of subjects: 89
Study 17610294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier-based adaptive Neyman test
Number of subjects: 0
Study 17610294 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavelet-based thresholding test
Number of subjects: 0
Study 17610294 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional linear regression models (FLRMs)
Number of subjects: 0
Study 16835968 — intervention group
Group type: EXPERIMENTAL
Intervention: DVd regimen with thalidomide (50 mg/d orally, increased to a maximum of 400 mg/d)
Number of subjects: 102
Study 16835968 — intervention group
Group type: COMPARATOR
Intervention: DVd regimen alone
Number of subjects: 102
Study 12639763 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (conjugated equine oestrogen 0.625 mg and medroxyprogesterone acetate 2.5 mg)
Number of subjects: 47
Study 12639763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12639763 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 47
Study 10928223 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2.5 mg risedronate
Number of subjects: 120
Study 10928223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 10928223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical 15 mg risedronate (2 out of 12 weeks)
Number of subjects: 120
Study 8959812 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 0
Study 1533165 — intervention group
Group type: EXPERIMENTAL
Intervention: High thoracic epidural analgesia (TEA) with bupivacaine 0.375% plus sufentanil 1:200,000 (5 micrograms/mL) combined with general anesthesia (midazolam/N2O)
Number of subjects: 54
Study 1533165 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) with midazolam and sufentanil
Number of subjects: 54
Study 2862196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulae with bacteria-retaining filters
Number of subjects: 209
Study 2862196 — intervention group
Group type: COMPARATOR
Intervention: Cannulae without bacteria-retaining filters
Number of subjects: 209
Study 30567457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone-binding globulin (SHBG)
Number of subjects: 5553
Study 30567457 — intervention group
Group type: EXPERIMENTAL
Intervention: Total testosterone
Number of subjects: 5553
Study 30567457 — intervention group
Group type: EXPERIMENTAL
Intervention: Free testosterone
Number of subjects: 5553
Study 29609070 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy (proton pump inhibitor plus amoxicillin for 14 days, and clarithromycin plus metronidazole for the initial 7 days)
Number of subjects: 352
Study 29609070 — intervention group
Group type: COMPARATOR
Intervention: Bismuth quadruple therapy (pantoprazole, bismuth, tetracycline, and metronidazole for 14 days)
Number of subjects: 352
Study 29609070 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy
Number of subjects: 352
Study 29609070 — intervention group
Group type: COMPARATOR
Intervention: Bismuth quadruple therapy
Number of subjects: 352
Study 26890438 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational Diabetes Mellitus (GDM)
Number of subjects: 763
Study 26890438 — intervention group
Group type: COMPARATOR
Intervention: No Gestational Diabetes Mellitus (No GDM)
Number of subjects: 763
Study 26890438 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite adverse outcomes
Number of subjects: 763
Study 26890438 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed preeclampsia with GDM
Number of subjects: 763
Study 26890438 — intervention group
Group type: COMPARATOR
Intervention: Superimposed preeclampsia without GDM
Number of subjects: 763
Study 26890438 — intervention group
Group type: EXPERIMENTAL
Intervention: Superimposed preeclampsia
Number of subjects: 763
Study 26890438 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of stay in neonatal intensive care unit
Number of subjects: 763
Study 24055515 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-reported duplex ultrasound (DU) scans prior to treatment
Number of subjects: 1702
Study 24055515 — intervention group
Group type: EXPERIMENTAL
Intervention: Site-reported duplex ultrasound (DU) scans at 12-month follow-up
Number of subjects: 1702
Study 24055515 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler angle alignment errors
Number of subjects: 1702
Study 24055515 — intervention group
Group type: EXPERIMENTAL
Intervention: UCL review of prior-to-treatment scans
Number of subjects: 1702
Study 24055515 — intervention group
Group type: EXPERIMENTAL
Intervention: UCL review of follow-up scans
Number of subjects: 1702
Study 24055515 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS vs CEA reclassification rates
Number of subjects: 1702
Study 22057579 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 10 mg
Number of subjects: 30
Study 22057579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19288181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resumed anticoagulation
Number of subjects: 608
Study 19288181 — intervention group
Group type: COMPARATOR
Intervention: Stopped anticoagulation
Number of subjects: 608
Study 19288181 — intervention group
Group type: COMPARATOR
Intervention: Normal D-dimer
Number of subjects: 608
Study 19288181 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal D-dimer
Number of subjects: 608
Study 16962674 — intervention group
Group type: EXPERIMENTAL
Intervention: AV sequential pacing at septum (DDDspt)
Number of subjects: 42
Study 16962674 — intervention group
Group type: COMPARATOR
Intervention: AV sequential pacing at RV apex (DDDapx)
Number of subjects: 42
Study 16962674 — intervention group
Group type: COMPARATOR
Intervention: Atrial pacing (AAI)
Number of subjects: 42
Study 15876304 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 20
Study 15876304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15876304 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust mite provocations
Number of subjects: 20
Study 12394665 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active treatment program
Number of subjects: 52
Study 12394665 — intervention group
Group type: COMPARATOR
Intervention: Less active training program (control group)
Number of subjects: 52
Study 12394665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 10091909 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional maximum likelihood logistic method
Number of subjects: 0
Study 10091909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric logistic method
Number of subjects: 0
Study 10091909 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate adjustment
Number of subjects: 0
Study 10091909 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified (multicenter) and multivariate (multivisit) analyses
Number of subjects: 0
Study 10091909 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional odds model
Number of subjects: 0
Study 8852495 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (Cardura) 2-8 mg once daily or 8 mg b.i.d.
Number of subjects: 30
Study 8852495 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (Capoten) 25-50 mg b.i.d.
Number of subjects: 30
Study 8852495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (Procardia-XL) 30-60 mg once daily
Number of subjects: 30